TTA Archives 2005-2012

MedApps, Inc. has announced the granting of regulatory clearance for over-the-counter use of its D-PAL Remote Patient Monitoring System for Diabetes by the U.S. Food and Drug Administration (FDA). D-PAL gives a new way for people with diabetes “to automatically transfer their daily glucose readings from their D-PAL integrated glucose monitors directly to a central server for records storage and review by healthcare professionals.” Full details in press release.